These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 23170032)

  • 1. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
    Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L; Denaro A; Agustoni F; Bajetta E
    J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
    Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
    Hatoum HT; Lin SJ; Buchner D; Cox D
    Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.